IFNG and hepatocellular carcinoma: Sun et al. used the rAd expressing IL-2 (rAd-IL-2) in the HCC tumor model, and the results showed that rAd-IL-2 can stimulate the proliferation of T cells and production of memory T cells in mice with HCC, induce tumor-specific cytotoxic T lymphocyte response and increase IFN-γ release, thereby inhibiting the proliferation and development of HCC, which can be an effective method for clinical immunotherapy of HCC [64].